Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of amonafide L-malate plus cytarabine and daunorubicin in acute myeloid leukemia
2007-004427-38Phase 3Terminated
- Sponsor
- Antisoma
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amonafide in acute myeloid leukemia (AML) (2 arms), sponsored by Antisoma. Primary endpoints: Rate of complete remission (CR) plus complete remission with incomplete hematopoietic recovery (CRi) and Durable CR + CRi (≥30 days). Started Oct 2008; status: terminated.
02
Drugs
amonafide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2007-004427-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004427-38.